These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 37092231)

  • 1. Implications of Tau Dysregulation in Huntington's Disease and Potential for New Therapeutics.
    Mees I; Nisbet RM; Hannan AJ; Renoir T
    J Huntingtons Dis; 2023; 12(1):1-13. PubMed ID: 37092231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease.
    Gratuze M; Noël A; Julien C; Cisbani G; Milot-Rousseau P; Morin F; Dickler M; Goupil C; Bezeau F; Poitras I; Bissonnette S; Whittington RA; Hébert SS; Cicchetti F; Parker JA; Samadi P; Planel E
    Hum Mol Genet; 2015 Jan; 24(1):86-99. PubMed ID: 25205109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faulty splicing and cytoskeleton abnormalities in Huntington's disease.
    Fernández-Nogales M; Santos-Galindo M; Hernández IH; Cabrera JR; Lucas JJ
    Brain Pathol; 2016 Nov; 26(6):772-778. PubMed ID: 27529534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive immunization against phosphorylated tau improves features of Huntington's disease pathology.
    Alpaugh M; Masnata M; de Rus Jacquet A; Lepinay E; Denis HL; Saint-Pierre M; Davies P; Planel E; Cicchetti F
    Mol Ther; 2022 Apr; 30(4):1500-1522. PubMed ID: 35051614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Phosphoproteomics Reveals Extensive Protein Phosphorylation Dysregulation in the Cerebral Cortex of Huntington's Disease Mice Prior to Onset of Symptoms.
    Mees I; Tran H; Roberts A; Lago L; Li S; Roberts BR; Hannan AJ; Renoir T
    Mol Neurobiol; 2022 Apr; 59(4):2456-2471. PubMed ID: 35083661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
    Dufour BD; McBride JL
    Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-occurrence of mixed proteinopathies in late-stage Huntington's disease.
    St-Amour I; Turgeon A; Goupil C; Planel E; Hébert SS
    Acta Neuropathol; 2018 Feb; 135(2):249-265. PubMed ID: 29134321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of tau pathologies in Huntington's disease.
    Baskota SU; Lopez OL; Greenamyre JT; Kofler J
    Lab Invest; 2019 Jul; 99(7):1068-1077. PubMed ID: 30573872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease.
    Ibrahim KS; El Mestikawy S; Abd-Elrahman KS; Ferguson SSG
    J Neurosci; 2023 Jun; 43(23):4365-4377. PubMed ID: 37055181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Regulation of Tau Exon 2 and 10 Isoforms in Huntington's Disease Brain.
    Petry S; Nateghi B; Keraudren R; Sergeant N; Planel E; Hébert SS; St-Amour I
    Neuroscience; 2023 May; 518():54-63. PubMed ID: 35868517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein changes in synaptosomes of Huntington's disease knock-in mice are dependent on age and brain region.
    Sapp E; Seeley C; Iuliano M; Weisman E; Vodicka P; DiFiglia M; Kegel-Gleason KB
    Neurobiol Dis; 2020 Jul; 141():104950. PubMed ID: 32439598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal mutant huntingtin deposition correlates with CAG repeat length and symptom onset, but not neuronal loss in Huntington's disease.
    Layburn FE; Tan AYS; Mehrabi NF; Curtis MA; Tippett LJ; Turner CP; Riguet N; Aeschbach L; Lashuel HA; Dragunow M; Faull RLM; Singh-Bains MK
    Neurobiol Dis; 2022 Nov; 174():105884. PubMed ID: 36220612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
    Seo H; Kim W; Isacson O
    Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.
    Flament J; Hantraye P; Valette J
    Methods Mol Biol; 2018; 1780():285-301. PubMed ID: 29856025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
    Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
    Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington's disease patients.
    Liu P; Smith BR; Huang ES; Mahesh A; Vonsattel JPG; Petersen AJ; Gomez-Pastor R; Ashe KH
    Acta Neuropathol Commun; 2019 Jul; 7(1):111. PubMed ID: 31358058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant huntingtin alters Tau phosphorylation and subcellular distribution.
    Blum D; Herrera F; Francelle L; Mendes T; Basquin M; Obriot H; Demeyer D; Sergeant N; Gerhardt E; Brouillet E; Buée L; Outeiro TF
    Hum Mol Genet; 2015 Jan; 24(1):76-85. PubMed ID: 25143394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
    Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
    J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.